TGR-1202: Preliminary Phase I data

Preliminary data from 21 evaluable patients relapsed or refractory CLL or NHL in the open-label, dose-escalation, U.S. Phase I UTX-TGR-103 trial showed that ublituximab in combination with TGR-1202 was well tolerated with infusion-related reactions reported as the most common adverse event. The only grade 3/4 adverse event reported in >10% of patients was neutropenia. In 5 evaluable patients with CLL/small lymphocytic leukemia (SLL), ublituximab plus TGR-1202 led to 4 partial responses and 1 case of stable disease. In 10 evaluable patients with NHL or Richter’s Syndrome, ublituximab plus TGR-1202 led to a disease control rate (DCR) of 90% and 2 of 5 patients with diffuse large B cell lymphoma (DLBCL) achieved a partial response. Data were presented at the Pan Pacific Lymphoma meeting in Koloa.

TGR-1202 is in Phase I testing to treat relapsed or refractory hematologic malignancies. In 2012, Rhizen partnered with TG Therapeutics to develop Rhizen’s TGR-1202 for hematologic cancers and autoimmune diseases (see BioCentury, Aug. 20, 2012). ...